TCB Capital Advisors is honored to support visionary companies like Altoida and Gregor Diagnostics who are making a lasting impact on the future of healthcare.

TCB Capital Advisors is thrilled to congratulate our esteemed board member, Dr. Ted Witek, for being honored with the Yale School of Public Health’s Distinguished Alumni Award.

David Leichner's interview with Sam Libby, President & Managing Director of TCB Capital Advisors

New Day Diagnostics is pleased to announce that the Extraordinary General Meeting of Epigenomics AG (Frankfurt General Standard: ECX1), a molecular diagnostics company focused on blood testing for the early detection of cancer, has approved the acquisition agreement between the two organizations. The agreement's completion will further enhance New Day Diagnostics' ability to improve lives by empowering people with innovative, accessible diagnostics.

TCB Capital Advisors is thrilled to announce the appointment of Nishant Sachdev as Director, further solidifying its position as a leading healthcare-focused advisory firm.

New Day Diagnostics LLC reinforces commitment to early cancer intervention with intention to acquire the assets of Epigenomics AG, as advised by TCB Capital Advisors.

Epigenomics AG officially entered into an agreement on the acquisition of almost all its assets with New Day Diagnostics LLC.

TCB Capital Advisors acted as the exclusive financial advisor for the merge of EDP Biotech and New Day Diagnostics.

Sam Libby joins EDP Biotech Corporation as Head of Mergers & Acquisitions and Corporate Development to expand investments and create new corporate relationship opportunities as the company grows.